NeuroSense Therapeutics Stock (NASDAQ: NRSN)

NeuroSense Therapeutics Stock (NASDAQ:NRSN), Trade Ideas

NeuroSense Therapeutics

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

NeuroSense’s (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 

Biotech

Penny Stocks

General

BIIB

NRSN

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and ultimately death within two to five years from diagnosis. Each year, about 5,000 people in the U.S.

NeuroSense&#39;s (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

News

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AAOI

ALLR

ARVN

ASAN

ASPN

AVAV

BCRX

CANO

CHSN

CJET

CLIN

CZOO

FLNC

GBNH

JNVR

LEJU

LGHL

LOVE

MESA

MLGO

NVNI

OPTN

PHIO

PHVS

PLAY

POWL

RELI

RENT

SERA

SFIX

SOAR

TGTX

WBUY

YEXT

Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results.

Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

U.S. stocks traded higher this morning, following the release of economic reports on Wednesday.

Following the market opening Wednesday, the Dow traded up 0.21% to 36,200.86 while the NASDAQ rose 0.28% to 14,270.30. The S&amp;P 500 also rose, gaining, 0.32% to 4,581.88.

US Stocks Higher; Private Payrolls Rise By 103,000 In November

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics Ltd

Barrington Research analyst James Goss maintains Imax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) with a Outperform and maintains $24 price target.

Price Target

Analyst Ratings

IMAX

Barrington Research Maintains Outperform on Imax, Maintains $24 Price Target

In an era of blossoming cannabis markets, North America stands out with significant milestones as Massachusetts and Canada reveal positive sales figures.
<h3 class="wp-block-heading">Massachusetts&#8217; Green Milestone: Surpassing $6 Billion</h3>
<a href="https://www.benzinga.com/topic/massachusetts-cannabis">Massachusetts</a> has set an impressive record, with cannabis establishments collectively crossing the $6 billion threshold in gross sales. Not surprisingly, a single-day sales record was smashed on April 20, as cannabis enthusiasts celebrated, amassing $8.5 million in transactions, <a href="https://masscannabiscontrol.com/2024/04/massachusetts-marijuana-establishments-surpass-6-billion-in-gross-sales-in-lead-up-to-4-20-and-set-single-sales-day-record-on-consumer-holiday/" target="_blank" rel="noreferrer noopener">noted</a> a press release from the Cannabis Control Commission (CCC). This robust growth signals not just a triumph for the industry but also for the economic and regulatory frameworks in place.
"I continue to be encouraged by these sales milestones because they show that the industry is strong and efficiently regulated, both spurring economic development and critical tax revenue for the Commonwealth and providing safe, tested products for consumers and patients alike," said Ava Callender Concepcion, acting chair of the CCC.
Read also: <a href="https://www.benzinga.com/markets/cannabis/24/04/38022665/massachusetts-cannabis-market-hits-record-highs-faces-regulatory-challenges-and-more" target="_blank" rel="noreferrer noopener">Massachusetts&#8217; Cannabis Market Hits Record Highs, Faces Regulatory Challenges, And More</a>
According to the CCC's sales and product distribution <a href="https://masscannabiscontrol.com/open-data/sales-and-product-distribution/">data</a>, medical cannabis made $62.5 million in sales in 2024. Massachusetts' delivery operators are also thriving, generating $3.1 million in sales in 2024 and contributing $26.3 million in sales to the state&#8217;s cannabis market since their first deliveries in 2021.
<h3 class="wp-block-heading">Canada&#8217;s Slow Climb: Provincial Perspectives</h3>
Across the northern border, Canada&#8217;s retail cannabis sales are showing modest growth. According to the latest <a href="https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=2010005601&amp;pickMembers%5B0%5D=2.30&amp;pickMembers%5B1%5D=3.1&amp;pickMembers%5B2%5D=4.1&amp;cubeTimeFrame.startMonth=12&amp;cubeTimeFrame.startYear=2017&amp;cubeTimeFrame.endMonth=05&amp;cubeTimeFrame.endYear=2024&amp;referencePeriods=20171201%2C20240501">release</a> from Statistics Canada, the nation tallied over CA$376 million ($274.9 million) in February 2024 alone, showcasing a resilient industry despite fluctuating global economic currents.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="976" height="687" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25142318/canadafeb24.png" alt="" class="wp-image-309428" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25142318/canadafeb24.png 976w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25142318/canadafeb24-300x211.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25142318/canadafeb24-768x541.png 768w" sizes="(max-width: 976px) 100vw, 976px" /><figcaption class="wp-element-caption">Canada&#8217;s monthly cannabis retail sales in millions of CA$&#x7C; Source: Statistics Canada. Table 20-10-0056-01</figcaption></figure>
Ontario leads the charge with CA$145,7 million ($106 million), followed closely by Alberta and British Columbia, underscoring a nationwide embrace of cannabis products.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Geography</td>
<td>Feb-23</td>
<td>Feb-24</td>
<td class="has-text-align-center" data-align="center">YoY Sales Growth %</td>
</tr>
<tr>
<td>Nova Scotia</td>
<td>CA$ 8,4 million</td>
<td>CA$ 12,6 million</td>
<td class="has-text-align-center" data-align="center">49.1%</td>
</tr>
<tr>
<td>Newfoundland and Labrador</td>
<td>CA$ 5,6 million</td>
<td>CA$ 7,0 million</td>
<td class="has-text-align-center" data-align="center">26.3%</td>
</tr>
<tr>
<td>Yukon</td>
<td>CA$ 788 thousand</td>
<td>CA$ 968 thousand</td>
<td class="has-text-align-center" data-align="center">22.8%</td>
</tr>
<tr>
<td>Manitoba</td>
<td>&nbsp;CA$ 14,3 million</td>
<td>CA$ 16,8 million</td>
<td class="has-text-align-center" data-align="center">17.2%</td>
</tr>
<tr>
<td>New Brunswick</td>
<td>CA$ 6,1 million</td>
<td>CA$ 7,0 million</td>
<td class="has-text-align-center" data-align="center">14.9%</td>
</tr>
<tr>
<td>Prince Edward Island</td>
<td>CA$ 1,7 million</td>
<td>CA$ 1,9 million</td>
<td class="has-text-align-center" data-align="center">12.2%</td>
</tr>
<tr>
<td>Alberta</td>
<td>CA$ 65,0 million</td>
<td>CA$ 72,0 million</td>
<td class="has-text-align-center" data-align="center">10.8%</td>
</tr>
<tr>
<td>Quebec</td>
<td>CA$ 45,1 million</td>
<td>CA$ 49,0 million</td>
<td class="has-text-align-center" data-align="center">8.5%</td>
</tr>
<tr>
<td>Saskatchewan</td>
<td>CA$ 13,5 million</td>
<td>CA$ 13,4 million</td>
<td class="has-text-align-center" data-align="center">-0.4%</td>
</tr>
<tr>
<td>Ontario</td>
<td>CA$ 151,1 million</td>
<td>CA$ 145,7 million</td>
<td class="has-text-align-center" data-align="center">-3.6%</td>
</tr>
<tr>
<td>British Columbia</td>
<td>CA$ 56,8 million</td>
<td>&nbsp;CA$ 48,3 million</td>
<td class="has-text-align-center" data-align="center">-15.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Statistics Canada. Sales for the Northwest Territories and Nunavut regions were not added to the report.</figcaption></figure>
However, despite the 1.7% year-over-year growth in the cannabis sector, <a href="https://www.benzinga.com/topic/canada-cannabis">Canada&#8217;s sales</a> have seen a downtrend for the second consecutive month:
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25143828/canadaall-1024x456.png" alt="" class="wp-image-309448" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25143828/canadaall-1024x456.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25143828/canadaall-300x134.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25143828/canadaall-768x342.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25143828/canadaall-1536x684.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25143828/canadaall.png 1541w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Canada monthly cannabis retail sales in millions of CA$&#x7C; Source: Statistics Canada. Table 20-10-0056-01</figcaption></figure>
As Canada grapples with a two-month sales dip and Massachusetts celebrates its record sales, these fluctuations depict a nuanced canvas of North America&#8217;s cannabis industry, evolving with consumer trends and regulatory landscapes.
Read also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38420095/cannabis-companies-gains-u-s-versus-canada-averages-can-be-deceiving-irrational-mar" target="_blank" rel="noreferrer noopener">Cannabis Companies&#8217; Gains &#8211; U.S. Versus Canada: Averages Can Be Deceiving, Irrational Market Behavior To Blame?</a>

Cannabis

Retail Sales

Massachusetts Cannabis Sales Soar Past $6B Record, Canada Sees Steady 1.7% Year-Over-Year Growth

Boise Cascade's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCC#NYSE">BCC</a>) short percent of float has fallen 15.29% since its last report. The company recently reported that it has 1.16 million shares sold short, which is 4.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.24 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Boise Cascade Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714072524_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Boise Cascade has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Boise Cascade's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Boise Cascade's peer group average for short interest as a percentage of float is 4.21%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Boise Cascade?

Seagate Tech Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STX#NYSE">STX</a>) short percent of float has fallen 6.4% since its last report. The company recently reported that it has 8.80 million shares sold short, which is 5.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.89 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Seagate Tech Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714072518_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Seagate Tech Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Seagate Tech Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Seagate Tech Hldgs's peer group average for short interest as a percentage of float is 6.37%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(STX) - Analyzing Seagate Tech Hldgs's Short Interest

Carlyle Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CG#NYSE">CG</a>) short percent of float has fallen 5.73% since its last report. The company recently reported that it has 15.49 million shares sold short, which is 7.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.03 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Carlyle Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714072513_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Carlyle Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Carlyle Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Carlyle Group's peer group average for short interest as a percentage of float is 2.49%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Carlyle Group's Recent Short Interest

WIIM

KLAC

LRCX

LSCC

MPWR

Shares of semiconductor stocks are trading higher in possible anticipation of Intel's earnings report. The sector recently gained following strong earnings from Texas Instruments.

Semiconductor stocks have been in the spotlight lately, with ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) and Globalfoundries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) trading near their 52-week lows. 
These companies are part of the MANGO acronym, a term introduced by BofA Securities analyst Vivek Arya. ON and Globalfoundries — along with Marvell Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), Advanced Micro Devices, Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Analog Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) — are sector leaders and aim to mirror the success of FAANG stocks.
We highlighted these stocks earlier in our analysis: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38169084/what-is-the-most-undervalued-mango-semiconductor-stock-right-now">What Is The Most Undervalued MANGO (Semiconductor) Stock Right Now?</a>
ON Semiconductor, currently trading at around $66, has a 52-week range of $59.34 &#8211; $111.35, with the low of $59.34 recorded on April 22. On reports Q1 earnings on April 29, before the market open.
Globalfoundries, trading at around $48, has a 52-week range of $45.52 &#8211; $68.57, with the low of $45.52 also recorded on April 22, 2024. GFS reports Q1 earnings on May 7, before the market open.
<h2 class="wp-block-heading">MANGO Stocks Performance Overview</h2>
A look at the one-year price performance of MANGO stocks shows a mix of growth trajectories. 
<ul>
<li>Nvidia leads the pack with an impressive surge of +194.64%</li>
<li>Broadcom follows with +116.45%</li>
<li>Advanced Micro Devices boasts +98.07%. </li>
<li>Marvell and Analog Devices also showcased notable gains</li>
<li>GlobalFoundries and ON Semiconductor presented more modest figures, with declines of -22.42% and -11.90%, respectively.</li>
</ul>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>MANGO Stocks (Semis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symbol</td>
<td></td>
<td>Price</td>
<td>52W Range ($)</td>
<td>YTD Perf</td>
<td>1Y Perf</td>
<td>3Y Perf</td>
</tr>
<tr>
<td>NVDA</td>
<td></td>
<td>796.77</td>
<td>266.25 974.00</td>
<td>60.89%</td>
<td>194.64%</td>
<td>421.95%</td>
</tr>
<tr>
<td>ON</td>
<td></td>
<td>65.53</td>
<td>59.34 111.35</td>
<td>-21.55%</td>
<td>-11.90%</td>
<td>54.01%</td>
</tr>
<tr>
<td>AVGO</td>
<td></td>
<td>1,256.82</td>
<td>601.29 1,438.17</td>
<td>12.59%</td>
<td>98.07%</td>
<td>169.63%</td>
</tr>
<tr>
<td>ADI</td>
<td></td>
<td>196.5</td>
<td>154.99 204.20</td>
<td>-1.04%</td>
<td>5.10%</td>
<td>23.57%</td>
</tr>
<tr>
<td>GFS</td>
<td></td>
<td>47.31</td>
<td>45.52 68.57</td>
<td>-21.93%</td>
<td>-22.42%</td>
<td>&#8211;</td>
</tr>
<tr>
<td>AMD</td>
<td></td>
<td>151.74</td>
<td>81.02 227.30</td>
<td>2.94%</td>
<td>73.28%</td>
<td>83.35%</td>
</tr>
<tr>
<td>MRVL</td>
<td></td>
<td>64.85</td>
<td>37.71 85.76</td>
<td>7.53%</td>
<td>67.31%</td>
<td>40.67%</td>
</tr>
</tbody>
</table>
</figure>
Data Source: Seeking Alpha
With ON and Globalfoundries are trading around their 52-week lows, investors wonder whether they hold value. Let&#8217;s look at the valuations.
<h2 class="wp-block-heading">Most Undervalued MANGO Stock</h2>
Delving into the valuation metrics, ON Semiconductor and GLOBALFOUNDRIES appear to be undervalued compared to their peers.
We compared the MANGO stocks on the following basis:
<ol>
<li>Price-to-Earnings (P/E) Ratio:&nbsp;so investors can assess the relative valuation of MANGO stocks based on their earnings generation.</li>
<li>Enterprise Value-to-Sales (EV/Sales) Ratio:&nbsp;MANGO stocks may not have consistent profits but have strong revenue growth.</li>
</ol>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Symbol</td>
<td>P/E FWD</td>
<td>EV / Sales</td>
</tr>
<tr>
<td>NVDA</td>
<td>31.88</td>
<td>31.94</td>
</tr>
<tr>
<td>ON</td>
<td>15.32</td>
<td>3.55</td>
</tr>
<tr>
<td>AVGO</td>
<td>26.57</td>
<td>16.63</td>
</tr>
<tr>
<td>ADI</td>
<td>32.63</td>
<td>8.92</td>
</tr>
<tr>
<td>GFS</td>
<td>35.18</td>
<td>3.34</td>
</tr>
<tr>
<td>AMD</td>
<td>41.98</td>
<td>10.7</td>
</tr>
<tr>
<td>MRVL</td>
<td>45.49</td>
<td>10.82</td>
</tr>
</tbody>
</table>
</figure>
Data Source: Seeking Alpha
ON and Globalfoundries are relatively better valued than their MANGO stock peers.
Analysts also see potential in investing in these stocks:
<ul>
<li>ON Semiconductor commands a <a href="https://www.benzinga.com/quote/ON/analyst-ratings">consensus price target</a> of $73.33, suggesting an implied upside of 11.45% based on recent analyst ratings.</li>
<li>Globalfoundries is pegged with a <a href="https://www.benzinga.com/quote/GFS/analyst-ratings">consensus price target</a> of $60.33, hinting at a potential 27.26% upside, as per the latest analyst assessments.</li>
</ul>
As the semiconductor industry evolves, prudent analysis and strategic investment decisions will be pivotal in navigating this dynamic landscape. 
With varied performance trajectories and distinct valuation metrics, investors have diverse options to consider within the MANGO portfolio.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38355764/intels-inventory-issues-redditors-highlight-how-overstock-killed-their-margins-yet-">Intel&#8217;s Inventory Issues: Redditors Highlight How Overstock &#8216;Killed Their Margins,&#8217; Yet Analysts See Upside</a>
Image: Shutterstock

Equities

Long Ideas

Tech

AVGO

MRVL

NVDA

2 Semiconductor MANGO Stocks Trading Near 52-Week Lows As They Head Into Q1 Earnings

Telsey Advisory Group analyst Joseph Feldman maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Outperform and maintains $275 price target.

TSCO

Telsey Advisory Group Maintains Outperform on Tractor Supply, Maintains $275 Price Target

Communications Workers Of America Union Says AT&T Workers Authorize Strike; CWA Members At AT&T West In District 9 Have Voted Overwhelmingly To Authorize A Strike, If Necessary

TSLA

Tesla shares are trading higher on continued post-earnings strength.

<h3 class="wp-block-heading">House-Approved Marijuana Banking Bill Advances In Delaware Senate</h3>
A measure that advanced through Delaware House and seeks to put into effect a law under which banks doing business with licensed marijuana businesses would be protected got the green light at the state Senate committee this week.
On Wednesday, the legislation from Rep. Ed Osienski (D) and Sen. Trey Paradee (D) advanced through the Senate Health &amp; Social Services Committee.
The synopsis of <a href="https://legis.delaware.gov/BillDetail?legislationId=141114">House Bill 355</a> stipulates that the measure "clarifies that banks, credit unions, armored car services, and providers of accounting services are not subject to prosecution under Delaware law merely by providing lawful services to licensed businesses engaged in the production, distribution and sale of cannabis in Delaware."
<h3 class="wp-block-heading">Schumer Says Marijuana Reform Needs To Be A Bipartisan Effort</h3>
On a federal level, Senate Majority Leader Chuck Schumer (D-NY) listed a bipartisan marijuana banking bill as a priority in his chamber, <a href="https://www.marijuanamoment.net/senators-will-do-our-best-to-pass-marijuana-banking-bill-in-a-bipartisan-way-schumer-says/">reported</a> Marijuana Moment.
On Tuesday he said "trying to deal with" the Secure and Fair Enforcement Regulation (SAFER) Banking Act "and cannabis reform," is on the Senate's agenda. He was asked about what's next for the chamber's members following this week's passage of a foreign aid package.
"We've got a lot to do," Schumer said referring to "a bunch of different bills". He added that lawmakers need to "work in a bipartisan way," while doing "our best to get many of them done."
<h3 class="wp-block-heading">Georgia's Restrictive Hemp Measure Awaits Gov. Kemp's Approval</h3>
Georgia Gov. Brian Kemp has until May 7 to weigh in on a bill that seeks to further regulate and license the purchase of hemp products to those 21 and older.
Dubbed "The Georgia Hemp Farming Act," the bill from Republican Moultrie Sen. Sam Watson would mandate testing for all hemp-derived products, including CBD and Delta-8 edibles and drinks while prohibiting sales to minors.
Watson, whose legislation was approved by the state Senate late in the session, says his efforts are toward providing more protection for consumers, <a href="https://georgiarecorder.com/2024/04/23/bill-to-regulate-hemp-products-in-georgia-awaits-governors-signature-while-some-hope-for-veto/">reported</a> Georgia Recorder.
"We regulate tobacco, we regulate alcohol, we regulate food, yet we've got a ton of these products out there now that we're not regulating as a state to protect the people of our state," he said.&nbsp;"Kids go into these gas stations and buy gas and this stuff is being sold and nobody knows what's in it and nobody's checking it and that's just scary."
<h3 class="wp-block-heading">Louisiana Bill To Create Regulatory Framework For Legal Marijuana Advances Through Legislature</h3>
Meanwhile, in Louisiana, state House committee members gave the green light to a measure that would set up a regulatory framework for marijuana legalization, <a href="https://www.marijuanamoment.net/louisiana-lawmakers-approve-bill-to-create-marijuana-legalization-regulatory-framework/">reported</a> Marijuana Moment.
The bill builds on <a href="https://www.benzinga.com/markets/cannabis/21/06/21576197/louisiana-governor-signs-marijuana-decriminalization-bill-into-law">legislation</a> that decriminalized small amounts of cannabis possession <a href="https://www.benzinga.com/markets/cannabis/21/08/22293351/marijuana-possession-no-longer-criminal-offense-in-louisiana-cannabis-decriminalization-bill-goe">for personal use statewide in 2021.</a>
The measure from Rep. Edmond Jordan (D) was approved this week in the House Health and Welfare Committee in a unanimous vote.
This bill is a prerequisite for the passage of additional bills that would allow possession of cannabis and tax marijuana sales.
Under an adult-use cannabis program, those 21 and older would be allowed to purchase up to one ounce of cannabis daily and apply for a license to grow up to six plants for personal use, with a cap of 12 plants per household.
Now read: <a href="https://www.benzinga.com/markets/cannabis/23/06/32897422/louisiana-governor-signs-marijuana-expungement-legislation-into-law">Louisiana Governor Signs Marijuana Expungement Legislation Into Law</a>

Government

Regulations

Politics

Marijuana Reform On Fast Track In These States As Sen. Schumer Stresses The Need For A Bipartisan Effort

Maxim Group analyst Michael Diana maintains Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) with a Buy and raises the price target from $70 to $78.

ENVA

Maxim Group Maintains Buy on Enova International, Raises Price Target to $78

Macquarie analyst Chad Beynon maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Neutral and raises the price target from $192 to $205.

Macquarie Maintains Neutral on Hilton Worldwide Holdings, Raises Price Target to $205

Thursday,&nbsp;Labcorp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) reported first-quarter sales increased 4.6% to $3.18 billion, beating the consensus of $3.12 billion. Base Business grew 6.7%.
The increase was due to organic revenue of 2.3%, acquisitions, net of divestitures of 1.8%, and foreign&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38426008/labcorp-announces-2024-first-quarter-results" rel="noreferrer noopener">currency translation of 0.5%</a>.&nbsp;
The 2.3% increase in organic revenue was driven by a 4.2% increase in the company&#8217;s organic Base Business, partially offset by a (1.9%) decrease in COVID-19 PCR testing (COVID-19 Testing).&nbsp;
The adjusted operating income margin for the quarter was 14.3%, almost unchanged from 14.7% a year ago.
Diagnostics Laboratories revenue for the quarter was&nbsp;$2.48&nbsp;billion, an increase of 4.1%.
Total volume increased by 3.4% as acquisition volume, net of divestitures contributed 2.2%, while organic volume increased by 1.2%.&nbsp;
Organic volume was up due to a 2.6% increase in the Base Business, including the negative impact&nbsp;from adverse weather&nbsp;of approximately 1%.&nbsp;Price/mix was up 1.9%.
Biopharma Laboratory Services revenue reached $710.9 million, up 7.5% due to organic growth of 5.1% and foreign currency translation of 2.4%.
Guidance:&nbsp;Labcorp expects 2024 adjusted EPS of $14.45-$15.35&nbsp;versus prior&nbsp;guidance&nbsp;of&nbsp;$14.30-$15.40&nbsp;and consensus of&nbsp;$14.82.
Labcorp&#8217;s&nbsp;2024 sales are expected to increase by 4.8%-6.4% compared to prior guidance of 4.7%-6.5%, Y/Y.
The guidance includes Diagnostics Laboratories sales growth guidance of 4.8%-6.0% and Biopharma Laboratory Services sales growth of 3.7%-5.7%, compared to prior guidance of 3.2%-4.8% and 5.5%-7.5%, respectively.
On&nbsp;Wednesday, the company said it will acquire bankrupt genetic test maker&nbsp;Invitae&nbsp;Corporation&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NVTA#OTC">NVTA</a>) for $239 million, a few months after the genetic test maker&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/02/36938401/softbank-backed-genetic-testing-invitaes-descent-from-7b-valuation-to-near-bankruptcy" rel="noreferrer noopener">filed for bankruptcy.</a>
Labcorp expects this transaction would generate approximately $275 million-$300 million in annual revenue, with&nbsp;the majority in specialty testing areas such as&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38420784/labcorp-announces-winning-bid-for-select-assets-of-invitae" rel="noreferrer noopener">oncology and rare diseases</a>.
William Blair&nbsp;suggests investors may seek clarification regarding the deal due to Invitae&#8217;s increased cash burn. If Invitae can control this, the acquisition could enhance its portfolio by utilizing Labcorp&#8217;s infrastructure, especially in oncology and rare diseases testing.&nbsp;
Labcorp&#8217;s aggressive M&amp;A approach, with over&nbsp;$475 million&nbsp;spent recently, may not significantly boost segment growth but could create long-term benefits by expanding solutions and customer reach in a changing market.
Price Action: LH shares are down 4.7% at $197.86 at last check Thursday.
Now Read: <a href="https://www.benzinga.com/markets/equities/24/04/38436183/magnificent-7-tumble-wipe-out-300-billion-on-metas-weak-guidance-q1-stagflation-woes">Magnificent 7 Tumble, Wipe Out $300 Billion On Meta&#8217;s Weak Guidance, Q1 Stagflation Woes</a>
Image generated using artificial intelligence via Midjourney.

Analyst Color

Large Cap

Guidance

Health Care

Laboratory Corporation Of America Holdings

NVTA

Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal

Kaspa's (CRYPTO:KAS) price has decreased 3.84% over the past 24 hours to $0.12. This is contrary to the coins performance over the past week where it has experienced an up-trend of 3.0%, moving from $0.12 to its current price.
The chart below compares the price movement and volatility for Kaspa over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1714071822_0.png" alt="price_chart" />
Kaspa's trading volume has climbed 38.0% over the past week along with the circulating supply of the coin, which has increased 0.59%. This brings the circulating supply to 23.09 billion, which makes up an estimated 80.44% of its max supply of 28.70 billion. According to our data, the current market cap ranking for KAS is #46 at $2.80 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1714071822_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Cryptocurrency Kaspa Falls More Than 3% In 24 hours

A coalition of 20 U.S. Democratic lawmakers sent a letter on Wednesday to the Drug Enforcement Administration (DEA) and Department of Justice, calling for the prompt removal of marijuana from Schedule I of the Controlled Substances Act (CSA).
Led by Sens. Elizabeth Warren (D-Mass.) and John Fetterman (D-Penn.), along with Reps. Earl Blumenauer (D-Ore.) and Barbara Lee (D-Calif.), the letter stressed the urgency of the matter, telling DEA Administrator Anne Milgram and Attorney General Merrick Garland that it's been eight months since the Department of Health and Human Services (HHS) <a href="https://www.benzinga.com/markets/cannabis/23/08/34120876/health-officials-to-dea-ease-federal-restrictions-on-cannabis-will-this-set-stage-for-legalizati">recommended the DEA reclassify cannabis</a> from Schedule I to Schedule III a year-and-a-half since President Joe Biden <a href="https://www.benzinga.com/markets/cannabis/22/10/29204539/biden-wants-to-see-marijuana-scheduling-review-as-quickly-as-possible-hhs-top-official-says">ordered a review of marijuana's classification</a>.
"It is time for the Drug Enforcement Administration (DEA) to act," the lawmakers <a href="https://www.warren.senate.gov/imo/media/doc/2024.04.24%20Follow-up%20letter%20to%20DEA%20on%20marijuana.pdf">wrote in the letter</a>, which was first reported by Huffington Post.
"Though marijuana is widely used and, according to HHS, is associated with fewer adverse outcomes than alcohol, it remains in the most restrictive schedule of the CSA. This placement produces a cascade of severe penalties for marijuana users and businesses, including for criminal records, immigration statuses, employment, taxation, health care, public housing, social services, and more," the group wrote.
<h1 class="wp-block-heading">Issues With The DEA Notwithstanding&#8230;</h1>
While acknowledging the potential for internal <a href="https://www.benzinga.com/markets/cannabis/24/03/37603576/dea-vs-white-house-agency-pushes-back-on-medical-benefits-of-cannabis-weed-stocks-wobble">disagreements within the DEA</a> and the White House, the letter stresses the need for swift action. 
"We urge you to promptly remove marijuana from Schedule I of the Controlled Substances Act (CSA). In recent months, we have sent you multiple letters explaining the importance of doing so," they continued.
<h1 class="wp-block-heading">Rescheduling Is Important, But Full Legalization Is Best</h1>
The letter cited previous correspondence reiterating that while reclassification to Schedule III would be a step forward, the ultimate solution lies in descheduling marijuana altogether.
"The longer marijuana remains scheduled in the CSA, the longer our communities face senselessly severe penalties and the longer the marijuana laws of the majority of U.S. states remain in conflict with federal law. Right now, the Administration has the opportunity to resolve more than 50 years of failed, racially discriminatory marijuana policy," the Democrats wrote.
In addition to praising Biden&#8217;s support for marijuana reform, the letter highlighted the significance of <a href="https://www.benzinga.com/markets/cannabis/24/04/38240431/biden-champions-cannabis-reform-and-pardon-as-election-pressure-mounts-marijuana-takes-center-st">Second Chance Month</a> as an opportunity to rectify the harms caused by marijuana&#8217;s scheduling.
"April 2024 — proclaimed "Second Chance Month" — is a prime opportunity to finally begin remedying the harms of marijuana's scheduling by removing marijuana from Schedule I," the 20 lawmakers said.
Photo: Benzinga edit with&nbsp;Billion Photos and Yarygin by Shutterstock

Legal

Senators Warren, Fetterman Plus 18 More Dems Tell DEA 'It's Time To Act' On Cannabis Rescheduling

OKB's (CRYPTO:OKB) price has decreased 3.04% over the past 24 hours to $53.0, continuing its downward trend over the past week of -5.0%, moving from $55.65 to its current price. 
The chart below compares the price movement and volatility for OKB over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1714071755_0.png" alt="price_chart" />
The trading volume for the coin has decreased 32.0% over the past week, while the overall circulating supply of the coin has increased 0.8% to over 60.00 million. This puts its current circulating supply at an estimated 20.0% of its max supply, which is 300.00 million. The current market cap ranking for OKB is #39 at $3.18 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1714071755_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cryptocurrency OKB Decreases More Than 3% Within 24 hours

Uniswap's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/uni/usd">UNI</a>) price has increased 3.22% over the past 24 hours to $7.98. Over the past week, UNI has experienced an uptick of over 11.0%, moving from $7.19 to its current price. As it stands right now, the coin's all-time high is $44.92. 
The chart below compares the price movement and volatility for Uniswap over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1714071745_0.png" alt="price_chart" />
The trading volume for the coin has increased 1.0% over the past week while the overall circulating supply of the coin has increased 0.04% to over 753.77 million which makes up an estimated 75.38% of its max supply, which is 1.00 billion. The current market cap ranking for UNI is #23 at $6.03 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1714071746_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$UNI

Cryptocurrency Uniswap Up More Than 3% In 24 hours

Across the recent three months, 5 analysts have shared their insights on YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated YETI Holdings and provided 12-month price targets. The average target is $41.8, accompanied by a high estimate of $48.00 and a low estimate of $38.00. This current average has decreased by 7.62% from the previous average price target of $45.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1714071692_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive YETI Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$40.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Altobello</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to YETI Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of YETI Holdings compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for YETI Holdings's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of YETI Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/YETI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on YETI Holdings analyst ratings.</a>
<h2>All You Need to Know About YETI Holdings</h2>
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
<h3>Understanding the Numbers: YETI Holdings's Finances</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: YETI Holdings displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 16.03%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.12%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 11.54%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): YETI Holdings's ROA excels beyond industry benchmarks, reaching 6.41%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.24, YETI Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

YETI

Demystifying YETI Holdings: Insights From 5 Analyst Reviews

Throughout the last three months, 6 analysts have evaluated Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Popular and provided 12-month price targets. The average target is $106.83, accompanied by a high estimate of $115.00 and a low estimate of $99.00. This current average has increased by 5.56% from the previous average price target of $101.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1714071680_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Popular by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Alexander Twerdahl</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Ben Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$99.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Popular. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Popular compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Popular's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Popular's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BPOP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Popular analyst ratings.</a>
<h2>About Popular</h2>
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
<h3>Popular's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Popular's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -1.72%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Popular's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 13.99%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Popular's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.97%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.13%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Popular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.22.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPOP

Popular Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

A rating of 87 puts Neurosense Therapeutics Ltd (NRSN) near the top of the Healthcare sector according to InvestorsObserver.Neurosense Therapeutics Ltd's score of 87 means that it ranks higher than 87% of stocks in the sector. In addition, its overall score of 46 ranks it higher than 46% of all stocks. NRSN has an Overall

Is Neurosense Therapeutics Ltd (NRSN) a Winner in the Healthcare Sector?

Neurosense Therapeutics Ltd. (NRSN) has released an update. NeuroSense Therapeutics Ltd. has reported promising results from their Phase 2b PARADIG...

NeuroSense's Positive ALS Trial Results and 2023 Finances

XXII, GRIN and XTIA are among mid-day movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NeuroSense Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nrsn-stock-quote/">NRSN</a>) just reported results for the fourth quarter of 2023.<ul><li>NeuroSense Therapeutics reported earnings per share of -16 cents. This was above the analyst estimate for EPS of -23 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/nrsn-stock-earnings-neurosense-therapeutics-for-q4-of-2023/">NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023

NeuroSense Therapeutics GAAP EPS of -$0.83 misses by $0.01

Neurosense Therapeutics Ltd. (NRSN) has released an update. NeuroSense Therapeutics Ltd. has entered a collaboration with Lonza to explore biomarke...

NeuroSense Partners with Lonza on ALS Biomarker Research

Neurosense Therapeutics Ltd. (NRSN) has released an update. NeuroSense Therapeutics Ltd. has reported promising top-line results from their Phase 2...

NeuroSense Advances ALS Therapy with Promising Trials

NeuroSense Therapeutics sheds 6%, on $4.5M direct private offering

NeuroSense Therapeutics sheds 6% on $4.5M direct private offering

Neurosense Therapeutics Ltd. (NRSN) has released an update. NeuroSense Therapeutics Ltd. has announced a pre-funded warrants offering, allowing hol...

NeuroSense Launches Pre-Funded Warrants Offering

ACOR

BTTR

CADL

DOGZ

EFSH

GCTS

HUBC

IMCC

MDIA

NEXI

Press Releases

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

Offerings

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Alliance Global Partners

Maxim Group